.jpg "Endo International Receives a Hold from Oppenheimer")
Oppenheimer analyst Christopher Liu maintained a Hold rating on Endo International (NASDAQ: ENDP) yesterday. The company’s shares closed on Friday at $6.10, close to its 52-week low of $5.27.
Liu noted:
“We adjust our model after ENDP reported 1Q18 financial results on May 8th, 2018. We continue to see the base business erode while Xiaflex and the sterile injectables segment grow, still unable to offset losses. In addition, as Vasostrict is a key product for the company (~35% of 1Q18 adjusted EBITDA), we expect investors to keep an eye out for the litigation against ENDP that could affect Vasostrict sales. As a positive, we like the merger with Somerset Therapeutics, a sterile injectable company, due to the strong synergy with ENDP’s own growing sterile injectable segment. We remain on the sidelines, however, as the company’s net debt leverage remains high at ~5.9x our 2018E EBITDA and as we wait for the company to return to growth.”
According to TipRanks.com, Liu is a 2-star analyst with an average return of 2.3% and a 60.0% success rate. Liu covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Zynerba Pharmaceuticals, and Perrigo Company plc.
Currently, the analyst consensus on Endo International is Hold and the average price target is $8.08, representing a 32.5% upside.
In a report issued on May 8, Cantor Fitzgerald also maintained a Hold rating on the stock with a $7 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.15 and a one-year low of $5.27. Currently, Endo International has an average volume of 4.95M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The company operates through the following segments: U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals and International Pharmaceuticals.
Read More on ENDP:
